You are welcome to participate in both tracks for additional education. Following the completion of the program, return to the dashboard to complete the post-test and evaluation.
FACULTY
Brandon Nathan, MD
Professor, Department of Pediatrics
Medical Director, Pediatric Ambulatory Services
Associate Division Director for Clinical Affairs, Division of Pediatric Endocrinology
Program Director, Pediatric Endocrinology Fellowship
University of Minnesota
Minneapolis, MN
PROGRAM OVERVIEW
This activity will provide a practice-based learning experience on the screening, early detection, and treatment of type 1 diabetes (T1D) by evoking the use of simulations that mimic real-world patient encounters. The activity will be divided into two tracks, a family medicine and an endocrinology track, each containing a different patient case that is specialty-specific and addresses the need and benefits for T1D screening, how to screen, appropriate referrals and follow-up post-screening, and identifying patients who can benefit from therapy to delay T1D progression. Through dialogue between the clinician and patient, supported by high impact visuals, interactive questions, as well as interspersed faculty video presentations, this activity allows for active learning to improve screening, follow-up, and early treatment decisions for T1D.
TARGET AUDIENCE
This activity is designed to meet the educational needs of Pediatric Endocrinologists, Adult Endocrinologists, Pediatricians, Primary Care Providers (PCPs), and Endocrine Nurses.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the clinical presentation of T1D in adults compared to children
- Identify appropriate autoantibody screening strategies for T1D, including type, frequency, and number
- Interpret results from screening protocols to drive management decisions
- Discuss the latest clinical evidence for efficacy and tolerability of newly approved and investigational immunomodulatory agents
- Implement strategies for appropriate clinical monitoring and early screening in individuals at highest risk
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hours.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 CPEU.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Speaker | Relationships | Manufacturer |
| Brandon Nathan, MD | Dr. Nathan reports payments for non-CME/CE services from Rubicon MD | |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of the activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Dominique Barton, BSN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Shpetim Karandrea, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Aimee Meissner Accreditation and Outcomes Coordinator Med Learning Group, has nothing to disclose.
- Emmanuella Foucault, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: September 30, 2024
EXPIRATION DATE: September 30, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY
Chuck Vega, MD, FAAFP
Health Sciences Clinical Professor
UC Irvine Department of Family Medicine
Director, UCI Program in Medical Education for the Latino Community
University of California Irvine
Irvine, CA
PROGRAM OVERVIEW
This activity will provide a practice-based learning experience on the screening, early detection, and treatment of type 1 diabetes (T1D) by evoking the use of simulations that mimic real-world patient encounters. The activity will be divided into two tracks, a family medicine and an endocrinology track, each containing a different patient case that is specialty-specific and addresses the need and benefits for T1D screening, how to screen, appropriate referrals and follow-up post-screening, and identifying patients who can benefit from therapy to delay T1D progression. Through dialogue between the clinician and patient, supported by high impact visuals, interactive questions, as well as interspersed faculty video presentations, this activity allows for active learning to improve screening, follow-up, and early treatment decisions for T1D.
TARGET AUDIENCE
This activity is designed to meet the educational needs of Pediatric Endocrinologists, Adult Endocrinologists, Pediatricians, Primary Care Providers (PCPs), and Endocrine Nurses.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the clinical presentation of T1D in adults compared to children
- Identify appropriate autoantibody screening strategies for T1D, including type, frequency, and number
- Interpret results from screening protocols to drive management decisions
- Discuss the latest clinical evidence for efficacy and tolerability of newly approved and investigational immunomodulatory agents
- Implement strategies for appropriate clinical monitoring and early screening in individuals at highest risk
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hours.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 CPEU.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Speaker | Relationships | Manufacturer |
| Chuck Vega, MD, FAAFP | Consultant | GlaxoSmithKline, Boehringer Ingelheim |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of the activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Dominique Barton, BSN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Shpetim Karandrea, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Aimee Meissner Accreditation and Outcomes Coordinator Med Learning Group, has nothing to disclose.
- Emmanuella Foucault, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: September 30, 2024
EXPIRATION DATE: September 30, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
